JWJoseph L. Wiemels

Joseph L. Wiemels

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Joseph L. Wiemels has a total of 21 co-authors. Here are the top co-authors by number of shared publications:

  • Freda E. Alexander

    Leukaemia Research Fund Centre, Institute of Cancer Research, London SW3 6JB, United Kingdom; Laboratory for Molecular Epidemiology, Department of Epidemiology and Biostatistics, University of California Medical School, San Francisco, CA 94143-0560; Immunogenetics Laboratory, St. Mary's Hospital, Manchester M13 0JH, United Kingdom; Academic Unit of Paediatric Oncology, Royal Manchester Children's and Christie Hospital National Health Service Trusts, Withington, Manchester M20 4BX, United...

    2 shared publications
  • Mel Greaves

    2 shared publications
  • Ana-Teresa Maia

    University of Algarve

    1 shared publication
  • Andrea Biondi

    Centro Ricerca Tettamanti, Clinica Pediatrica, University of Milan, Milan, Italy

    1 shared publication
  • Brian M. Dicks

    1 shared publication
  • G. Malcolm Taylor

    Leukaemia Research Fund Centre, Institute of Cancer Research, London SW3 6JB, United Kingdom; Laboratory for Molecular Epidemiology, Department of Epidemiology and Biostatistics, University of California Medical School, San Francisco, CA 94143-0560; Immunogenetics Laboratory, St. Mary's Hospital, Manchester M13 0JH, United Kingdom; Academic Unit of Paediatric Oncology, Royal Manchester Children's and Christie Hospital National Health Service Trusts, Withington, Manchester M20 4BX, United...

    1 shared publication

Latest Publications

  • In utero origin of t(8;21) AML1-ETO translocations in childhood acute myeloid leukemia

    by Joseph L. Wiemels, Zhijian Xiao, Patricia A. Buffler, Ana T. Maia, Xiaomei Ma, Brian M. Dicks, Martyn T. Smith, Luoping Zhang, James Feusner, John Wiencke, et al.

    Recent reports have established the prenatal origin of leukemia translocations and resultant fusion genes in some patients, including MLL-AF4 translocations in infants andTEL-AML1 translocations in children. We now report evidence for the prenatal origin of a translocation in childhood acute myeloid leukemia (AML). The t(8;21) AML1-ETO translocations were sequenced at the genomic level in 10 diagnostic leukemia samples from children with available neonatal Guthrie blood spots. Clonotypic genomic AML1-ETO sequences were detected in the Guthrie spots for 5 individuals, providing unambiguous evidence of prenatal origin in these cases. Two of these patients were older than 10 years of age at diagnosis, indicative of a protracted postnatal latency. Three of the patients were assessed for the persistence of genomic fusion sequences in complete clinical remission samples and were found to be positive. These data indicate that t(8;21) in childhood AML can arise in utero, possibly as an initiating event in childhood AML, and may establish a long-lived or stable parental clone that requires additional secondary genetic alterations to cause leukemia.


  • Methylenetetrahydrofolate reductase (MTHFR) polymorphisms and risk of molecularly defined subtypes of childhood acute leukemia

    by Joseph L. Wiemels, Rosalyn N. Smith, G. Malcolm Taylor, Osborn B. Eden, Freda E. Alexander, Mel F. Greaves, United Kingdom Childhood Cancer Study Investigators

    Low folate intake as well as alterations in folate metabolism as a result of polymorphisms in the enzyme methylenetetrahydrofolate reductase ( MTHFR ) have been associated with an increased incidence of neural tube defects, vascular disease, and some cancers. Polymorphic variants of MTHFR lead to enhanced thymidine pools and better quality DNA synthesis that could afford some protection from the development of leukemias, particularly those with translocations. We now report associations of MTHFR polymorphisms in three subgroups of pediatric leukemias: infant lymphoblastic or myeloblastic leukemias with MLL rearrangements and childhood lymphoblastic leukemias with either TEL - AML1 fusions or hyperdiploid karyotypes. Pediatric leukemia patients ( n = 253 total) and healthy newborn controls ( n = 200) were genotyped for MTHFR polymorphisms at nucleotides 677 (C→T) and 1,298 (A→C). A significant association for carriers of C677T was demonstrated for leukemias with MLL translocations ( MLL +, n = 37) when compared with controls [adjusted odd ratios (OR) = 0.36 with a 95% confidence interval (CI) of 0.15–0.85; P = 0.017]. This protective effect was not evident for A1298C alleles (OR = 1.14). In contrast, associations for A1298C homozygotes (CC; OR = 0.26 with a 95% CI of 0.07–0.81) and C677T homozygotes (TT; OR = 0.49 with a 95% CI of 0.20–1.17) were observed for hyperdiploid leukemias ( n = 138). No significant associations were evident for either polymorphism with TEL - AML1 + leukemias ( n = 78). These differences in allelic associations may point to discrete attributes of the two alleles in their ability to alter folate and one-carbon metabolite pools and impact after DNA synthesis and methylation pathways, but should be viewed cautiously pending larger follow-up studies. The data provide evidence that molecularly defined subgroups of pediatric leukemias have different etiologies and also suggest a role of folate in the development of childhood leukemia.


  • Microclustering ofTEL-AML1 translocation breakpoints in childhood acute lymphoblastic leukemia

    by Joseph L. Wiemels, Freda E. Alexander, Giovanni Cazzaniga, Andrea Biondi, Sharon P. Mayer, Mel Greaves

    TEL‐AML1 fusions are the most common chromosome translocations in childhood leukemia and often, if not always, occur in utero. We previously reported the genomic sequencing of nine TEL‐AML1 translocations and showed unique structural features of a breakpoint cluster region in TEL intron 5. We now report data on sequencing and mapping of TEL‐AML1 from an additional 11 patients and, using Monte Carlo statistical methods, have analyzed the intronic distribution of the 24 TEL‐AML1 fusion junctions sequenced to date. Compared to a null hypothesis of random breakpoint allocation within TEL intron 5 and AML1 introns 1 and 2, significant microclustering was evident on both TEL and AML1. In contrast to previous reports, the two strongest microclusters on TEL were 3′ to an unstable repeat region. AML1 demonstrated four highly significant microclusters, two of which were proximal to exons. We note the necessity of sequencing multiple breakpoints before the description of putative microcluster regions. TEL‐AML1 breakpoints may be distributed into microclusters because of specific DNA sequence or chromatin features in susceptible cells. We also report on additional features of breakpoints, including a complex t(12;3;21) in one patient and an inverted sequence in another.